China's National Medical Products Administration (NMPA) approved Innovent Biologics Inc.’s NDA for Dovbleron (taletrectinib), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for treating ...
Emergen Research Logo. The diabetic foot ulcer treatment market is expected to grow from an estimated USD 5.36 Billion in 2024 to USD 9.21 Billion in 2033, ...